

Nicola S Meagher

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1980650/publications.pdf>

Version: 2024-02-01

24
papers

660
citations

623734

14
h-index

610901

24
g-index

24
all docs

24
docs citations

24
times ranked

1287
citing authors

#	ARTICLE	IF	CITATIONS
1	MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 855-871.	2.8	8
2	Validated biomarker assays confirm that <i>ARID1A</i> loss is confounded with <i>MMR</i> deficiency, <i>CD8</i> ⁺ TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas. <i>Journal of Pathology</i> , 2022, 256, 388-401.	4.5	15
3	Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses. <i>Modern Pathology</i> , 2021, 34, 194-206.	5.5	21
4	Moving with the Times: The Health Science Alliance (HSA) Biobank, Pathway to Sustainability. <i>Biomarker Insights</i> , 2021, 16, 117727192110057.	2.5	9
5	Targeting the actin/tropomyosin cytoskeleton in epithelial ovarian cancer reveals multiple mechanisms of synergy with anti-microtubule agents. <i>British Journal of Cancer</i> , 2021, 125, 265-276.	6.4	7
6	A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. <i>Modern Pathology</i> , 2019, 32, 1834-1846.	5.5	54
7	Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials. <i>Gynecologic Oncology</i> , 2018, 150, 527-533.	1.4	14
8	Iatrogenic immunosuppression and risk of non-Hodgkin lymphoma in solid organ transplantation: A population-based cohort study in Australia. <i>British Journal of Haematology</i> , 2016, 174, 550-562.	2.5	22
9	High azathioprine dose and lip cancer risk in liver, heart, and lung transplant recipients: A population-based cohort study. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 1144-1152.e6.	1.2	23
10	Examining the quality of name code record linkage: what is the impact on death and cancer risk estimates? A validation study. <i>Australian and New Zealand Journal of Public Health</i> , 2015, 39, 141-147.	1.8	9
11	Longitudinal dose and type of immunosuppression in a national cohort of Australian liver, heart, and lung transplant recipients, 1984-2006. <i>Clinical Transplantation</i> , 2015, 29, 978-990.	1.6	6
12	The impact of blood-borne viruses on cause-specific mortality among opioid dependent people: An Australian population-based cohort study. <i>Drug and Alcohol Dependence</i> , 2015, 152, 264-271.	3.2	15
13	Survival After Cutaneous Melanoma in Kidney Transplant Recipients: A Population-Based Matched Cohort Study. <i>American Journal of Transplantation</i> , 2014, 14, 1368-1375.	4.7	42
14	Lymphoid neoplasm incidence by WHO subtype in Australia 1982-2006. <i>International Journal of Cancer</i> , 2014, 135, 2146-2156.	5.1	62
15	An audit of cancer of unknown primary notifications: A cautionary tale for population health research using cancer registry data. <i>Cancer Epidemiology</i> , 2014, 38, 460-464.	1.9	14
16	Comparison of De Novo Cancer Incidence in Australian Liver, Heart and Lung Transplant Recipients. <i>American Journal of Transplantation</i> , 2013, 13, 174-183.	4.7	81
17	Latitude gradients for lymphoid neoplasm subtypes in Australia support an association with ultraviolet radiation exposure. <i>International Journal of Cancer</i> , 2013, 133, 944-951.	5.1	39
18	De novo Cancer-Related Death in Australian Liver and Cardiothoracic Transplant Recipients. <i>American Journal of Transplantation</i> , 2013, 13, 1296-1304.	4.7	69

#	ARTICLE	IF	CITATIONS
19	The importance of blood-borne viruses in elevated cancer risk among opioid-dependent people: a population-based cohort study. <i>BMJ Open</i> , 2012, 2, e001755.	1.9	32
20	Medulloblastoma: Progress over time. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2012, 56, 227-234.	1.8	11
21	Governance approval for multisite, non-interventional research: what can Harmonisation of Multi-Centre Ethical Review learn from the New South Wales experience?. <i>Internal Medicine Journal</i> , 2012, 42, 127-131.	0.8	11
22	Retained role of surgery for olfactory neuroblastoma. <i>Head and Neck</i> , 2011, 33, 1486-1492.	2.0	16
23	Role of radiotherapy in early glottic carcinoma. <i>Head and Neck</i> , 2010, 32, 850-859.	2.0	54
24	Recurrent Nasopharyngeal Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 469-473.	1.3	26